Generic Industry’s Perspective on the New GMP Initiative May 21, 2003 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance.

Slides:

Advertisements

Similar presentations

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.

Advertisements

1 SANS Technology Institute - Candidate for Master of Science Degree 1 Automating Crosswalk between SP 800, 20 Critical Controls, and Australian Government.

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.

Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.

International Telecommunication Union Committed to connecting the world 4 th ITU Green Standards Week Mike Wood & Jack Rowley EMF Technical Group Leaders,

Industry Coalition on 21 CFR Part 11 Recommendations for Achieving Compliance with the Electronic Records and Electronic Signatures Regulation.

Collaboration between FDA and EMA

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

Frequently Asked Questions (FAQ) prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.

ICH Q9: Quality Risk Management

Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum 21 CFR Part 11 Considerations November 14, 2002.

Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.

Regulatory requirements and benefits converting to Continued Process Verification.

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Welcome ISO9001:2000 Foundation Workshop.

21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.

Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.

Quality By Design - A Generic Industry Perspective

Regulatory Update Ellen Leinfuss SVP, Life Sciences.

Organizational Gaps in Reaching the “Desired State” Helen Winkle.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.

Changes without Prior Approval Breakout Session Summary Rick Smith Aventis Pasteur, Inc.

Regulatory Perspective on Development of

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. REGULATORY INTELLIGENCE: INDUSTRY’S BEST PRACTICE OMICS 5 th International Pharmaceutical.

FAQs about the new regulatory framework Lucy Rhodes

A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.

1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.

An Industry Response to the Expected Control Room Management Rule Western Regional Gas Conference Daron Moore – El Paso Pipeline Group August 25, 2009.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,

ERM and the Pharmaceutical Industry. Risk  An innate part of every aspect of life, and the business environment is of no exception  Severity, both in.

PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

Earned Value Management Update Nancy L. Spruill Director, Acquisition Resources and Analysis Office of the Under Secretary of Defense (Acquisition, Technology.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.

FDA Part 11 Public Meeting Washington, DC June 11, 2004 Paul D’Eramo Executive Director Worldwide Policy & Compliance Management Quality & Compliance Services.

Supporting the right to know for trade in certain hazardous chemicals International High-level expert Conference on Chemical Safety and Rotterdam Convention:

ISO CONCEPTS Is a management standard, it is not performance or product standard. The underlying purpose of ISO 1400 is that companies will improve.

1 PAT Subcommittee Closing Report 12 March 2003 Tom Layloff Acting Chair.

ICH Quality Topics Update

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.

Royal Society of Chemistry Food Group Vision & Mission June 2015.

Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.

Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

BEST PRACTICES IN INTERNAL COMPLIANCE AUDITING Willis Ennis Director QA/RA.

Webinar On Transfer of Analytical Methods and Procedures according to USP 1224 Presented By Dr. Ludwig Huber Webinar On Transfer of Analytical Methods.

5. Presentación general de la iniciativa REDD+ SES 5. Presentation of the REDD+ SES Initiative.

Generic Industry’s Perspective on the New GMP Initiative 2002 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance TEVA.

Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.

Quality System.

Lesson 8: BRITE Seminar: GMP II

PhUSE Key Performance Indicator Initiative

ICH Q9: Quality Risk Management

ICH Q9: Quality Risk Management

Larry Kessler, Sc.D. Director

OECD good practices for setting up an RIA system Regional Capacity-Building Seminar on Regulatory Impact Assessment Istanbul, Turkey 20 November 2007.

Royal Society of Chemistry Food Group

DRAFT ISO 10007:2017 Revision Overview Quality management – Guidelines for configuration management ISO/TC176 TG 01.

Presentation transcript:

Generic Industry’s Perspective on the New GMP Initiative May 21, 2003 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance TEVA Pharmaceuticals USA

Risk-Based Approach Definition –Implementation –Benefits Dialogue –Guidance

Changes to Approved Applications Interim Specifications Development Report: –Guidelines –How to be used –No Negative Impact on Review –Goals

Pre-Approval Inspections No longer universally necessary –Except Novel Compounds & New Technologies Chemistry Reviewer Inspections –No Delays

Communications 483 Dispute Resolution Publish Internal FDA polices and Procedures Publish Control Documents Proceduralize Pre-ANDA meetings

Summary – Guidance & Procedures GPhA welcomes the opportunity to work with FDA, industry and academia on developing the science to create the procedures to allow for a new regulatory framework.